TABLE 3.
Effect of factors on mean percentage change from baseline in femoral neck BMD at 3 yr (strata I and II)
| Category | n | Mean % change in FN BMD
|
Least squares mean between-treatment difference (95% CI) | P value within category | P value interaction | |
|---|---|---|---|---|---|---|
| Zoledronic acid | Placebo | |||||
| Age (yr) | ||||||
| <70 | 959 | 4.33 | −0.76 | 5.09 (4.55, 5.62) | <0.0001 | 0.99 |
| 70–74 | 1015 | 4.09 | −0.96 | 5.05 (4.52, 5.57) | <0.0001 | |
| ≥75 | 1093 | 3.90 | −1.14 | 5.04 (4.53, 5.55) | <0.0001 | |
| Race | ||||||
| Asian | 469 | 4.37 | −0.49 | 4.85 (4.08, 5.63) | <0.0001 | 0.51 |
| Caucasian | 2390 | 4.08 | −0.96 | 5.04 (4.70, 5.38) | <0.0001 | |
| Other | 208 | 3.71 | −1.97 | 5.68 (4.50, 6.85) | <0.0001 | |
| Region | ||||||
| Americas | 1074 | 3.5 | −1.47 | 4.98 (4.47, 5.48) | <0.0001 | 0.70 |
| Asia | 459 | 4.35 | −0.48 | 4.82 (4.04, 5.61) | <0.0001 | |
| Europe | 1534 | 4.44 | −0.73 | 5.17 (4.74, 5.60) | <0.0001 | |
| Smoking | ||||||
| No | 2810 | 4.17 | −0.92 | 5.08 (4.77, 5.40) | <0.0001 | 0.58 |
| Yes | 257 | 3.35 | −1.42 | 4.77 (3.70, 5.84) | <0.0001 | |
| Femoral neck T-score and VFx status | ||||||
| OP, no VFx | 953 | 4.81 | −0.56 | 5.37 (4.82, 5.92) | <0.0001 | 0.004 |
| OP, VFx | 1258 | 4.44 | −0.92 | 5.36 (4.89, 5.83) | <0.0001 | |
| No OP, no VFx | 238 | 3.21 | −1.38 | 4.59 (3.53, 5.65) | <0.0001 | |
| No OP, VFx | 617 | 2.65 | −1.37 | 4.02 (3.36, 4.68) | <0.0001 | |
| Weight (kg) | ||||||
| <55 | 1040 | 3.92 | −1.29 | 5.21 (4.68, 5.74) | <0.0001 | 0.77 |
| 55–64 | 1067 | 3.97 | −1.10 | 5.07 (4.56, 5.58) | <0.0001 | |
| >64 | 957 | 4.43 | −0.50 | 4.93 (4.40, 5.46) | <0.0001 | |
| Height loss (cm) | ||||||
| <−5.65 | 1015 | 4.05 | −1.48 | 5.53 (5.00, 6.05) | <0.0001 | 0.10 |
| −5.65 to −3 | 1009 | 4.02 | −0.86 | 4.89 (4.37, 5.41) | <0.0001 | |
| >−3 | 972 | 4.26 | −0.53 | 4.79 (4.26, 5.31) | <0.0001 | |
| BMI (kg/m2) | ||||||
| <18 | 74 | 2.66 | −2.42 | 5.07 (3.07, 7.07) | <0.0001 | 0.27 |
| 18–24.9 | 1574 | 3.95 | −1.15 | 5.10 (4.67, 5.53) | <0.0001 | |
| 25–29.9 | 1064 | 4.39 | −0.90 | 5.29 (4.79, 5.79) | <0.0001 | |
| >30 | 350 | 4.22 | −0.07 | 4.28 (3.41, 5.16) | <0.0001 | |
| Total hip BMD (g/cm2) | ||||||
| 0.23–0.61 | 1035 | 4.72 | −1.27 | 5.98 (5.46, 6.51) | <0.0001 | <0.0001 |
| >0.61–0.68 | 1019 | 3.99 | −1.06 | 5.05 (4.52, 5.57) | <0.0001 | |
| >0.68–1.32 | 1006 | 3.56 | −0.55 | 4.10 (3.58, 4.63) | <0.0001 | |
| Prior BP use | ||||||
| No | 2604 | 4.3 | −0.86 | 5.16 (4.84, 5.49) | <0.0001 | 0.26 |
| Yes | 455 | 2.86 | −1.60 | 4.46 (3.67, 5.26) | <0.0001 | |
| Stratum | ||||||
| I | 2394 | 4.26 | −0.87 | 5.13 (4.79, 5.47) | <0.0001 | 0.40 |
| II | 673 | 3.53 | −1.29 | 4.81 (4.16, 5.47) | <0.0001 | |
| CrCl (ml/min) | ||||||
| <60 | 1361 | 3.88 | −1.31 | 5.18 (4.73, 5.64) | <0.0001 | 0.48 |
| ≥60 | 1706 | 4.27 | −0.69 | 4.96 (4.56, 5.37) | <0.0001 | |
Falls and walking distance had no effect on BMD change by category and so are not listed. CI, Confidence interval; BP, bisphosphonate; FN, femoral neck; OP, osteoporosis (femoral neck T-score ≤−2.5); VFx, vertebral fracture; CrCl, creatinine clearance.